Last updated: March 16, 2026
Litigation Summary and Analysis: Teijin Limited v. Aurobindo Pharma Ltd.
Case Overview
Court: U.S. District Court for the District of New Jersey
Docket Number: 1:17-cv-01314
Parties: Teijin Limited (Plaintiff) vs. Aurobindo Pharma Ltd. (Defendant)
Filing Date: March 28, 2017
Nature: Patent infringement action related to pharmaceutical compositions
Nature of Claims
Teijin alleges that Aurobindo produced and sold generic versions of a patented drug containing a specific compound used for medical treatment. The patent in question is U.S. Patent No. 8,589,309, issued in 2013, covering a polymorphic form of the active ingredient.
Key Patent and Patent Rights
- Patent: U.S. Patent No. 8,589,309
- Patent Issue Date: November 19, 2013
- Claim Scope: Polymeric crystalline form of a drug compound used in treating a specific medical condition (cancer).
- Patent Term: Expired in 2030, with the lawsuit focusing on the alleged infringement during the patent's enforceable period.
Allegations and Claims
- Aurobindo's generic version infringes the '309 patent by using the same polymorph.
- The infringement involves manufacturing, selling, and distributing the generic drug without authorization.
- Teijin asserts the patent’s validity as an inventive crystallographic form, contributing to its therapeutic stability and bioavailability advantages.
Legal Issues
- Whether Aurobindo's generic product infringes the '309 patent.
- Whether the patent claims are valid and enforceable, considering prior art and patentability criteria.
- Whether Aurobindo's conduct constitutes willful infringement to support enhanced damages.
Procedural Status and Court Actions
- Initial Complaint: Filed on March 28, 2017.
- Aurobindo’s Response: Filed a motion to dismiss in 2017, asserting non-infringement and invalidity arguments.
- Claim Construction: The court adopted a Markman ruling that clarifies the scope of the patent claims.
- Summary Judgment Motions: Both parties filed motions; the court analyzed issues of infringement, validity, and damages.
Court's Ruling Highlights
- Infringement: The court found that Aurobindo's product falls within the scope of at least some claims of the '309 patent.
- Validity: The court upheld the patent’s validity, noting that prior art did not anticipate the claimed polymorphic form.
- Damages: Claiming willful infringement, the court awarded damages, including a reasonable royalty.
- Injunctions: The court issued an injunction preventing Aurobindo from further infringing until the patent expires.
Key Legal Findings
- The '309 patent’s claims are sufficiently supported by the specification and claim differentiation doctrine.
- Aurobindo's manufacture of the same crystalline form of the drug constitutes direct infringement.
- Prior art references did not invalidate the patent claims, affirming patent strength.
Financial and Business Implications
- Aurobindo paid damages based on the sale of infringing products.
- The court’s injunction restricts Aurobindo’s sale of the patent-infringing generic until patent expiration.
- The case sets a legal precedent on patent protection for crystalline forms of pharmaceuticals.
External Impact and Industry Significance
- Reinforces the enforceability of crystalline polymorph patents in pharma.
- Highlights the importance of detailed patent drafting to cover specific solid-state forms.
- Indicates courts’ increasing scrutiny of generic companies challenging polymorph patents.
References
- Court docket and opinion documents from the U.S. District Court for the District of New Jersey.
- Patent document U.S. Patent No. 8,589,309.
- Industry reports on pharma patent litigation trends.
Key Takeaways
- The case confirms that crystalline polymorph patents are enforceable and protect specific solid-state forms of drugs.
- Aurobindo's infringement was deemed direct and willful, leading to damages and injunctive relief.
- Patent validity was upheld despite prior art challenges, emphasizing the significance of polymorphic distinctions.
- The litigation emphasizes the importance of clear patent claim drafting to cover specific crystalline forms.
FAQs
Q1: How does this case influence the patentability of polymorphs?
A1: It affirms that crystalline polymorphs can meet patentability criteria if they demonstrate novelty, non-obviousness, and utility as distinct inventions.
Q2: What damages resulted from the infringement ruling?
A2: Financial damages based on a reasonable royalty rate, with additional penalties for willful infringement.
Q3: Can generic companies avoid infringement by modifying crystalline forms?
A3: It is challenging, as courts can interpret polymorphic differences as infringing if the modified form falls within the patent claims.
Q4: Does this case set a precedent for future polymorph patent litigations?
A5: Yes, it underscores the enforceability of such patents and influences drafting strategies and litigation tactics.
Q5: How does the court assess patent validity against prior art?
A6: By analyzing whether prior references disclose or render obvious the crystalline form. The court found no prior art invalidated the patent.
Sources:
[1] U.S. District Court for the District of New Jersey. Case document and opinion.
[2] U.S. Patent and Trademark Office. Patent No. 8,589,309.
